Lowest Price Guaranteed From USD 4,799
Published
August 2023
Pages
190
View Count
1404
Example Insights
 |
 |
 |
 |
 |
.webp) |
.webp) |
 |
.webp) |
.webp) |
Report Description
The global plasma fractionation market is estimated to be worth $ 4.4 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of ~10% during the forecast period. Over the past two decades, the number of patients affected with rare diseases have increased tremendously. In fact, over 410 million people are currently suffering from rare and chronic disorders. Given the growing prevalence of the aforementioned disorders, the demand for plasma derived therapies that have proven to be effective treatment option, has also observed an incremental hike. In order to cater to the rising demand for these plasma-derived therapies, an uninterrupted supply of blood plasma becomes imperative. Currently, the US is the hub of plasma donation centers, with ~80% of the world’s plasma donation centers. In fact, the country alone supplies more than 70% of plasma to the plasma fractionator for the manufacturing of plasma-derived therapies after the process of plasma fractionation. It is worth mentioning that plasma fractionation is a crucial process to ensure separation and purification of key blood plasma components, such as immunoglobulins, albumins, anticoagulant factors and protease inhibitors. The refined blood plasma components / fractions then can be used for formulation of therapeutics. Recently, in April 2023, HYQVIA , a recombinant immunoglobulin was granted approval for its supplemental biologics license application (sBLA) regarding its expanded usage in the treatment of primary immunodeficiency in children (2-16 years). In fact, the plasma derived therapies hold immense significance as lifesaving treatments for patients worldwide, especially those afflicted with rare and complex diseases. Further, we believe that, as the need for these critical medicines rises, ongoing advancements in blood plasma fractionation and plasma manufacturing technology are anticipated to ensure timely access to those in need, in the foreseen future.
The Plasma Fractionation Market - Distribution by Type of Company (In-house Manufacturers and Contract Service Providers), Scale of Operation (Preclinical, Clinical and Commercial), Type of Plasma-derived Therapeutic Products Manufactured (Albumins, Coagulation Factors, Immunoglobulins, Protease Inhibitors and Other Plasma derived Products), Therapeutic Areas of Plasma-derived Products (Hematological Disorders, Hepatic Disorders, Immunological Disorders, Neurological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 market report features an extensive study of the current market landscape, market size and future opportunities associated with companies having plasma fractionation capabilities, during the given forecast period. The market research report highlights the efforts of several stakeholders engaged in this emerging and rapidly evolving segment of the biopharmaceutical industry. Key takeaways from the study of plasma fractionation market are briefly discussed below.
In the US, Europe and Canada, over 1,000 specialized donation centers facilitate plasma donation through a process known as plasmapheresis. This automated procedure separates plasma from red blood cells and other cellular components, which are returned to the donor. However, the COVID-19 pandemic resulted in ~20% reduction in plasma donations, leading to shortage in raw material supply for plasma derived therapies. To address the decline in plasma collection volume, various stakeholders, including government agencies, patient advocacy groups and plasma fractionation companies, launched awareness campaigns to encourage plasma donation.
In 2022, the three largest plasma fractionation companies, namely CSL Behring, Grifols and Takeda Pharmaceutical, reported a substantial increase in plasma donations, with collection volumes returning to pre-pandemic levels. Despite this positive development, various challenges still persist, as the process from plasma donation to patient administration can take several months. In order to overcome these challenges, a number of commercial plasma fractionators have acquired / built their own network of plasma collection centers in the US and EU. Notably, the market is dominated by a few key companies that have undertaken several efforts to ensure the supply of plasma. For instance, Takeda acquired BioLife Plasma Services in 2019, which at the time of acquisition had more than 140 plasma collection centers across four countries. In January 2022, Grifols acquired Prometic Plasma Resources Inc's plasma donation center in Canada, the former company’s first collection center in the region.
The plasma industry is actively exploring ways to enhance efficacy and reduce the cost of plasma-derived therapies through various measures, including adoption of new plasma fractionation technologies and increased automation. These efforts will aid to meet the rising demand for plasma-derived therapies and ensure patients' access to essential treatments. In April 2022, CSL Plasma adopted Rika Plasma Donation System, which claims to reduce the plasma donation procedure time by 30% while improving the donor experience. Such technological advancements in plasma collection are anticipated to assist in meeting the global demand for plasma, driving the plasma fractionation market during the forecast period.
The plasma fractionation market features a mix of large, mid-sized and small companies, that have the required expertise to manufacture various types of plasma derived products. The market is consolidated, with the large commercial plasma fractionators acquiring the smaller regional industry players. In 2017, CSL Behring acquired Wuhan Zhong Yuan Rui De Biological Products, a China based plasma fractionator with one manufacturing facility and four plasma collection centers. Grifols also acquired a plasma fractionation facility in Canada, with 1.5 million liter annual capacity, from South Korea based GC Pharma in October 2020. There have been more such instances of mergers and acquisitions for market consolidation.
At present, more than 35 companies fractionate plasma in-house to manufacture plasma therapies. Takeda, being one such in-house plasma fractionator, announced its plans to set up a new plasma therapy manufacturing facility in Osaka, Japan in March 2023. The plant will be built with an investment of $ 754 million and will be capable of plasma fractionation and end-to-end manufacturing of plasma derived therapies.
In terms of geographical presence, we have identified more than 85 plasma facilities, through which these companies perform plasma fractionation. The majority of these facilities are located in Asia-Pacific, followed by Europe and North America. Further, nearly 20% of the plasma fractionation companies have the capability to operate at all the scales of operation from preclinical to commercial.
Human blood plasma contains more than 4,000 proteins, each having essential physiological functions and potential therapeutic benefits. However, ~30 such proteins are suitable for manufacturing various plasma-derived medicinal products to treat a wide range of indications. List of plasma-derived products that received Biologics License Applications (BLAs) approval include alpha-1 proteinase inhibitor, antihemophilic factor, antithrombin, C1 esterase inhibitor, coagulation factors, fibrin, fibrinogen, immune globulins, protein C and thrombin. In addition to the aforementioned products, several other blood plasma products have also been approved by the USFDA. Examples of these include albumins, alpha antitrypsin, antihemophilic factor (recombinant), antihemophilic factor / von willebrand factor complex, anti-inhibitor coagulant complex, antithrombin (recombinant), corifact, profilnine SD - factor IX complex, kcentra (prothrombin complex concentrate, human), protein C concentrate, thrombin and von willebrand factor (recombinant).
The global plasma fractionation market is estimated to be worth around $ 4.4 billion in 2023. Driven by the rising demand for blood plasma therapies, along with advancement in fractionation technologies, the plasma fractionation market is anticipated to grow at a CAGR of around 10%, during the forecast period 2023-2035. Currently, the global market for plasma manufacturing is dominated by plasma fractionation companies involved in fractionating immunoglobulins. This segment captures more than 45% of the market share and is likely to grow at a CAGR of more than 9% during the forecast period.
Presently, close to 45% of the demand is generated from North America. However, in the coming years, owing to the rising awareness about plasma derived products and high potency of plasma derived medicinal products, demand for blood plasma fractionates in Asia-Pacific region is likely to increase significantly at a much faster rate as compared to other geographies.
In terms of supply of plasma-derived therapies, the market potential of Asia-Pacific is anticipated to experience significant market growth in the coming years. In fact, the Asia-Pacific region is projected to grow at an annualized rate of over 11% by 2035. This incline can be attributed to the region's largest consumer base and the presence of manufacturers in China, India, Australia and South Korea.
Examples of key plasma fractionation companies (which have also been captured in this report) engaged in this industry include Baxter, Grifols, Kedrion, Octapharma, CSL and Takeda Pharmaceutical. This market report includes an easily searchable excel database of the companies involved in plasma fractionation worldwide.
Several recent developments have taken place in the field of blood plasma fractionation. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments as defined in the below table:
| Key Report Attributes | Details | |
|
Historical Trend |
2017-2022 |
|
|
Base Year |
2022 |
|
|
Forecast Period |
2023-2035 |
|
|
Market Size 2023 |
$4.4 billion |
|
|
CAGR |
~10% | |
|
Type of Company |
|
|
|
Scale of Operation |
|
|
|
Type of Plasma-derived Therapeutic Products Manufactured |
|
|
|
Therapeutic Areas of Plasma-derived Products |
|
|
|
Demand Across Key Geographical Regions |
|
|
|
Supply Across Key Geographical Regions |
|
|
|
Key Companies Profiled |
(Full list of 35+ companies captured in the market landscape analysis of the report) |
|
|
Customization Scope |
15% Free Customization Option | |
|
PowerPoint Presentation (Complimentary) |
Available |
|
|
Excel Data Packs (Complimentary) |
|
|
The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different regions. Amongst other elements, the research report includes:
One of the key objectives of this market report was to estimate the current opportunity and the future market growth potential of the global plasma fractionation market over the forecast period. We have provided an informed estimate on the likely evolution of the plasma fractionation market for the period 2023-2035. Our year-wise projections of the current and forecasted market have been further segmented based on relevant parameters, such as type of company (in-house manufacturers and contract service providers), scale of operation (preclinical, clinical and commercial), type of plasma-derived therapeutic products manufactured (albumins, coagulation factors, immunoglobulins, protease inhibitors and other plasma-derived products), therapeutic areas of plasma-derived products (hematological disorders, hepatic disorders, immunological disorders, neurological disorders and other disorders), demand across key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and supply across key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Plasma Fractionation Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Blood Plasma
3.2.1. Plasma Collection
3.2.2. Plasma Screening
3.2.3. Plasma Fractionation
3.3. Applications of Plasma Fractionation
3.4. Challenges Associated with Plasma Fractionation
3.5. Need for Third-party Service Providers
3.5.1. Overview of Third-party Service Providers
3.6. Future Perspectives
4. PLASMA FRACTIONATION: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Plasma Fractionation: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region)
4.2.4. Analysis by Location of Headquarters (Country)
4.2.5. Analysis by Year of Establishment and Location of Headquarters (Region)
4.2.6. Analysis by Company Size and Location of Headquarters (Region)
4.2.7. Analysis by Type of Company
4.2.8. Analysis by Location of Plasma Fractionation Facilities (Region)
4.2.9. Analysis by Location of Plasma Collection Facility
4.2.10. Analysis by Availability of Patented / Proprietary Technology
4.2.11. Analysis by Additional Fractionation Capabilities
4.2.12. Analysis by Scale of Operation
4.2.13. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
4.2.14. Analysis by Therapeutic Areas of Plasma-derived Products
4.2.15. Analysis by End Users
4.2.16. Information on Plasma Fractionation Capacity and Accreditation / Certification
4.2.17. Information on Upcoming Plasma Fractionation Facilities
4.2.18. Information on Companies Previously Involved in Plasma Fractionation
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: In-house Manufacturers
5.4.1. Players based in North America and Europe
5.4.2. Players based in Asia-Pacific and Rest of the World
5.5. Company Competitiveness Analysis: In-house Manufacturers and Contract Service Providers
5.5.1. Players based in North America and Europe
5.5.2. Players based in Asia-Pacific and Rest of the World
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Baxter
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Plasma Fractionation Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.3. Companies Headquartered in Europe
6.3.1. Grifols
6.3.1.1. Company Overview
6.3.1.2. Financial Information
6.3.1.3. Plasma Fractionation Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Kedrion
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Plasma Fractionation Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Octapharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Plasma Fractionation Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.4. Companies Headquartered in Asia-Pacific
6.4.1. CSL
6.4.1.2. Company Overview
6.4.1.3. Financial Information
6.4.1.4. Plasma Fractionation Portfolio
6.4.1.5. Recent Developments and Future Outlook
6.4.2. Takeda Pharmaceutical
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Plasma Fractionation Portfolio
6.4.2.4. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Plasma Fractionation: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Purpose of Agreement
7.3.5. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
7.3.6. Analysis by Type of Partner
7.3.7. Analysis by Year of Partnership and Type of Partner
7.3.8. Analysis by Type of Partnership and Type of Partner
7.3.9. Most Active Players: Analysis by Number of Partnerships
7.4. Analysis by Geography
7.4.1. Local and International Agreements
7.4.2. Intracontinental and Intercontinental Agreements
8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Expansion Models
8.3. Plasma Fractionation: Recent Expansions
8.3.1. Analysis by Year of Expansion
8.3.2. Analysis by Type of Expansion
8.3.3. Analysis by Year and Type of Expansion
8.3.4. Analysis by Type of Facility
8.3.5. Analysis by Location of Expanded Facility
8.3.6. Analysis by Year and Location of Expanded Facility
8.3.7. Analysis by Plasma-derived Therapeutic Products Manufactured
8.3.8. Most Active Players: Analysis by Number of Expansions
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.2.1. Annual Plasma Fractionation Capacity
9.2.1.1. Analysis by Company Size
9.2.1.2. Analysis by Type of Plasma-derived Therapeutic Products Manufactured
9.2.1.3. Analysis by Scale of Operation
9.2.2. Analysis by Location of Plasma Fractionation Facility
9.2.3 .Analysis by Location of Headquarters
9.3. Concluding Remarks
10. MARKET SIZING AND OPPURTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Plasma Fractionation Market (Historical, Base and Forecasted Scenario), 2017-2035
10.3.1. Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035
10.3.1.1. Plasma Fractionation Market for In-house Manufacturers, 2023-2035
10.3.1.2. Plasma Fractionation Market for Contract Service Providers, 2023-2035
10.3.2. Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035
10.3.2.1. Plasma Fractionation Market for Preclinical, 2023-2035
10.3.2.2. Plasma Fractionation Market for Clinical, 2023-2035
10.3.2.3. Plasma Fractionation Market for Commercial, 2023-2035
10.3.3. Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035
10.3.3.1. Plasma Fractionation Market for Albumins, 2023-2035
10.3.3.2. Plasma Fractionation Market for Coagulation Factors, 2023-2035
10.3.3.3. Plasma Fractionation Market for Immunoglobulins, 2023-2035
10.3.3.4. Plasma Fractionation Market for Protease Inhibitors, 2023-2035
10.3.3.5. Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035
10.3.4. Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035
10.3.4.1. Plasma Fractionation Market for Hematological Disorders, 2023-2035
10.3.4.2. Plasma Fractionation Market for Hepatic Disorders, 2023-2035
10.3.4.3. Plasma Fractionation Market for Immunological Disorders, 2023-2035
10.3.4.4. Plasma Fractionation Market for Neurological Disorders, 2023-2035
10.3.4.5. Plasma Fractionation Market for Other Disorders, 2023-2035
10.3.5. Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035
10.3.5.1. Plasma Fractionation Market in North America, 2023-2035
10.3.5.2. Plasma Fractionation Market in Europe, 2023-2035
10.3.5.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035
10.3.5.4. Plasma Fractionation Market in Rest of the World, 2023-2035
10.3.6. Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035
10.3.6.1. Plasma Fractionation Market in North America, 2023-2035
10.3.6.2. Plasma Fractionation Market in Europe, 2023-2035
10.3.6.3. Plasma Fractionation Market in Asia-Pacific, 2023-2035
10.3.6.4. Plasma Fractionation Market in Rest of the World, 2023-2035
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Current Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Recent Expansions
Figure 2.4 Executive Summary: Capacity Analysis
Figure 2.5 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Components of Blood
Figure 3.2 Components of Blood Plasma
Figure 3.3 Process of Plasmapheresis
Figure 3.4 Good Manufacturing Practices for Blood Screening
Figure 3.5 Steps Involved in Plasma Fractionation
Figure 3.6 Target Therapeutic Areas of Plasma-derived Therapies
Figure 3.7 Advantages of Third-party Service Providers
Figure 4.1 Plasma Fractionators: Distribution by Year of Establishment
Figure 4.2 Plasma Fractionators: Distribution by Company Size
Figure 4.3 Plasma Fractionators: Distribution by Location of Headquarters (Region)
Figure 4.4 Plasma Fractionators: Distribution by Location of Headquarters (Country)
Figure 4.5 Plasma Fractionators: Distribution by Year of Establishment and Location of Headquarters (Region)
Figure 4.6 Plasma Fractionators: Distribution by Company Size and Location of Headquarters (Region)
Figure 4.7 Plasma Fractionators: Distribution by Type of Company
Figure 4.8 Plasma Fractionators: Distribution by Location of Plasma Fractionation Facilities (Region)
Figure 4.9 Plasma Fractionators: Distribution by Location of Plasma Collection Facility
Figure 4.10 Plasma Fractionators: Distribution by Availability of Patented / Proprietary Technology
Figure 4.11 Plasma Fractionators: Distribution by Additional Fractionation Capabilities
Figure 4.12 Plasma Fractionators: Distribution by Scale of Operation
Figure 4.13 Plasma Fractionators: Distribution by Type of Plasma-derived Therapeutic Products Manufactured
Figure 4.14 Plasma Fractionators: Distribution by Therapeutic Areas of Plasma-derived Products
Figure 4.15 Plasma Fractionators: Distribution by End Users
Figure 5.1 In-house Manufacturers: Players based in North America and Europe
Figure 5.2 In-house Manufacturers: Players based in Asia-Pacific and Rest of the World
Figure 5.3 In-house Manufacturers and Contract Service Providers: Players based in North America and Europe
Figure 5.4 In-house Manufacturers and Contract Service Providers: Players based in Asia-Pacific and Rest of the World
Figure 6.1 Baxter: Annual Revenues, 2018-Q1 2023 (USD Billion)
Figure 6.2 Grifols: Annual Revenues, 2018-Q1 2023 (EUR Million)
Figure 6.3 Kedrion: Annual Revenues, 2018-2022 (EUR Million)
Figure 6.4 Octapharma: Annual Revenues, 2018-2022 (EUR Billion)
Figure 6.5 CSL: Annual Revenues, FY 2018 - H1 FY 2023 (USD Million)
Figure 6.5 Takeda Pharmaceutical: Annual Revenues, FY 2018 - FY 2022 (JPY Billion)
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Distribution of Partnerships
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Purpose of Agreement
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Plasma-derived Therapeutic Products Manufactured
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.7 Most Active Players: Distribution by Number of Partnerships
Figure 7.8 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 7.9 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 8.1 Recent Expansions: Cumulative Year-wise Distribution of Expansions
Figure 8.2 Recent Expansions: Distribution by Type of Expansion
Figure 8.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 8.4 Recent Expansions: Distribution by Type of Facility
Figure 8.5 Recent Expansions: Distribution by Location of Expanded Facility
Figure 8.6 Recent Expansions: Distribution by Year and Location of Expanded Facility
Figure 8.7 Recent Expansions: Distribution by Plasma-derived Therapeutic Products Manufactured
Figure 8.8 Most Active Players: Distribution by Number of Expansions
Figure 9.1 Annual Plasma Fractionation Capacity: Distribution by Range of Installed Capacity
Figure 9.2 Annual Plasma Fractionation Capacity: Distribution by Company Size
Figure 9.3 Annual Plasma Fractionation Capacity: Distribution by Type of Plasma-derived Therapeutic Products Manufactured
Figure 9.4 Annual Plasma Fractionation Capacity: Distribution by Scale of Operation
Figure 9.5 Plasma Fractionation Capacity: Distribution by Location of Plasma Fractionation Facilities
Figure 9.6 Plasma Fractionation Capacity: Distribution by Location of Headquarters (in Million Liters)
Figure 10.1 Global Plasma Fractionation Market (Historical Trends and Forecasted Estimates), 2017-2035 (USD Billion)
Figure 10.2 Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035 (USD Billion)
Figure 10.3 Plasma Fractionation Market for In-house Manufacturers, 2023-2035 (USD Billion)
Figure 10.4 Plasma Fractionation Market for Contract Service Providers, 2023-2035 (USD Billion)
Figure 10.5. Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035 (USD Billion)
Figure 10.6 Plasma Fractionation Market for Preclinical Operations, 2023-2035 (USD Billion)
Figure 10.7 Plasma Fractionation Market for Clinical Operations, 2023-2035 (USD Billion)
Figure 10.8 Plasma Fractionation Market for Commercial Operations, 2023-2035 (USD Billion)
Figure 10.9 Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035 (USD Billion)
Figure 10.10 Plasma Fractionation Market for Albumins, 2023-2035 (USD Billion)
Figure 10.11 Plasma Fractionation Market for Coagulation Factors, 2023-2035 (USD Billion)
Figure 10.12 Plasma Fractionation Market for Immunoglobulins, 2023-2035 (USD Billion)
Figure 10.13 Plasma Fractionation Market for Protease Inhibitors, 2023-2035 (USD Billion)
Figure 10.14 Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035 (USD Billion)
Figure 10.15 Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035 (USD Billion)
Figure 10.16 Plasma Fractionation Market for Hematological Disorders, 2023-2035 (USD Billion)
Figure 10.17 Plasma Fractionation Market for Hepatic Disorders, 2023-2035 (USD Billion)
Figure 10.18 Plasma Fractionation Market for Immunological Disorders, 2023-2035 (USD Billion)
Figure 10.19 Plasma Fractionation Market for Neurological Disorders, 2023-2035 (USD Billion)
Figure 10.20 Plasma Fractionation Market for Other Disorders, 2023-2035 (USD Billion)
Figure 10.21 Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035 (USD Billion)
Figure 10.22 Plasma Fractionation Market for North America, 2023-2035 (USD Billion)
Figure 10.23 Plasma Fractionation Market for Europe, 2023-2035 (USD Billion)
Figure 10.24 Plasma Fractionation Market for Asia-Pacific, 2023-2035 (USD Billion)
Figure 10.25 Plasma Fractionation Market for Rest of the World, 2023-2035 (USD Billion)
Figure 10.26 Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035 (USD Billion)
Figure 10.27 Plasma Fractionation Market for North America, 2023-2035 (USD Billion)
Figure 10.28 Plasma Fractionation Market for Europe, 2023-2035 (USD Billion)
Figure 10.29 Plasma Fractionation Market for Asia-Pacific, 2023-2035 (USD Billion)
Figure 10.30 Plasma Fractionation Market for Rest of the World, 2023-2035 (USD Billion)
Figure 11.1 Concluding Remarks: Current Market Landscape of Plasma Fractionators
Figure 11.2 Concluding Remarks: Partnerships and Collaborations
Figure 11.3 Concluding Remarks: Recent Expansions
Figure 11.4 Concluding Remarks: Capacity Analysis
Figure 11.5 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
Figure 11.6 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)
Table 4.1 List of Plasma Fractionators
Table 4.2 Plasma Fractionators: Information on Plasma Fractionation Facilities
Table 4.3 Plasma Fractionators: Information on Plasma Collection Facilities
Table 4.4 Plasma Fractionators: Information on Patented / Proprietary Technology / Process Used
Table 4.5 Plasma Fractionators: Information on Additional Fractionation Capabilities
Table 4.6 Plasma Fractionators: Information on Scale of Operation
Table 4.7 Plasma Fractionators: Information on Type of Plasma-derived Therapeutic Products Manufactured
Table 4.8 Plasma Fractionators: Information on Therapeutic Areas of Plasma-derived Products
Table 4.9 Plasma Fractionators: Information on End Users
Table 4.10 Plasma Fractionators: Information on Plasma Fractionation Capacity and Accreditation / Certification
Table 4.11 Plasma Fractionators: Information on Upcoming Plasma Fractionation Facilities
Table 4.12 Plasma Fractionators: Information on Companies Previously Involved in Plasma Fractionation
Table 4.13 Plasma Fractionation: List of Additional Players
Table 6.1 Plasma Fractionation: List of Companies Profiled
Table 6.2 Baxter: Company Snapshot
Table 6.3 Baxter: Plasma Fractionation Portfolio
Table 6.4 Baxter: Recent Developments and Future Outlook
Table 6.5 Grifols: Company Snapshot
Table 6.6 Grifols: Plasma Fractionation Portfolio
Table 6.7 Grifols: Recent Developments and Future Outlook
Table 6.8 Kedrion: Company Snapshot
Table 6.9 Kedrion: Plasma Fractionation Portfolio
Table 6.10 Kedrion: Recent Developments and Future Outlook
Table 6.11 Octapharma: Company Snapshot
Table 6.12 Octapharma: Plasma Fractionation Portfolio
Table 6.13 Octapharma: Recent Developments and Future Outlook
Table 6.14 CSL: Company Snapshot
Table 6.15 CSL: Plasma Fractionation Portfolio
Table 6.16 CSL: Recent Developments and Future Outlook
Table 6.17 Takeda Pharmaceutical: Company Snapshot
Table 6.18 Takeda Pharmaceutical: Plasma Fractionation Portfolio
Table 6.19 Takeda Pharmaceutical: Recent Developments and Future Outlook
Table 7.1 Plasma Fractionation: Partnerships and Collaborations
Table 7.2 Plasma Fractionation: Information on Location of Partner (Country and Region)
Table 8.1 Plasma Fractionation: Recent Expansions
Table 8.2 Recent Expansions: Information on Type of Plasma-derived Therapeutic Products Manufactured
Table 9.1 Annual Plasma Fractionation Capacity: Average Capacity Per Facility by Company Size of Fractionators (Sample Data Set)
Table 9.2 Annual Plasma Fractionation Capacity: Distribution by Company Size
Table 13.1 Plasma Fractionators: Distribution by Year of Establishment
Table 13.2 Plasma Fractionators: Distribution by Company Size
Table 13.3 Plasma Fractionators: Distribution by Location of Headquarters (Region)
Table 13.4 Plasma Fractionators: Distribution by Location of Headquarters (Country)
Table 13.5 Plasma Fractionators: Distribution by Year of Establishment and Location of Headquarters (Region)
Table 13.6 Plasma Fractionators: Distribution by Company Size and Location of Headquarters (Region)
Table 13.7 Plasma Fractionators: Distribution by Type of Company
Table 13.8 Plasma Fractionators: Distribution by Location of Plasma Fractionation Facilities (Region)
Table 13.9 Plasma Fractionators: Distribution by Location of Plasma Collection Facility
Table 13.10 Plasma Fractionators: Distribution by Availability of Patented / Proprietary Technology
Table 13.11 Plasma Fractionators: Distribution by Additional Fractionation Capabilities
Table 13.12 Plasma Fractionators: Distribution by Scale of Operation
Table 13.13 Plasma Fractionators: Distribution by Type of Plasma-derived Therapeutic Products Manufactured
Table 13.14 Plasma Fractionators: Distribution by Therapeutic Areas of Plasma-derived Products
Table 13.15 Plasma Fractionators: Distribution by End Users
Table 13.16 Baxter: Annual Revenues, 2018-Q1 2023 (USD Billion)
Table 13.17 Grifols: Annual Revenues, 2018-Q1 2023 (EUR Million)
Table 13.18 Kedrion: Annual Revenues, 2018-2022 (EUR Million)
Table 13.19 Octapharma: Annual Revenues, 2018-2022 (EUR Billion)
Table 13.20 CSL: Annual Revenues, FY 2018 - H1 FY 2023 (USD Million)
Table 13.21 Takeda Pharmaceutical: Annual Revenues, FY 2018 - FY 2022 (JPY Billion)
Table 13.22 Partnerships and Collaborations: Cumulative Year-wise Distribution of Partnerships
Table 13.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.25 Partnerships and Collaborations: Distribution by Purpose of Agreement
Table 13.26 Partnerships and Collaborations: Distribution by Type of Plasma-derived Therapeutic Products Manufactured
Table 13.27 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 13.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 13.30 Most Active Players: Distribution by Number of Partnerships
Table 13.31 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 13.32 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Table 13.33 Recent Expansions: Cumulative Year-wise Distribution of Expansions
Table 13.34 Recent Expansions: Distribution by Type of Expansion
Table 13.35 Recent Expansions: Distribution by Year and Type of Expansion
Table 13.36 Recent Expansions: Distribution by Type of Facility
Table 13.37 Recent Expansions: Distribution by Location of Expanded Facility
Table 13.38 Recent Expansions: Distribution by Year and Location of Expanded Facility
Table 13.39 Recent Expansions: Distribution by Plasma-derived Therapeutic Products Manufactured
Table 13.40 Most Active Players: Distribution by Number of Expansions
Table 13.41 Annual Plasma Fractionation Capacity: Distribution by Range of Installed Capacity
Table 13.42 Annual Plasma Fractionation Capacity: Distribution by Company Size
Table 13.43 Annual Plasma Fractionation Capacity: Distribution by Type of Plasma-derived Therapeutic Products Manufactured
Table 13.44 Annual Plasma Fractionation Capacity: Distribution by Scale of Operation
Table 13.45 Plasma Fractionation Capacity: Distribution by Location of Plasma Fractionation Facilities
Table 13.46 Plasma Fractionation Capacity: Distribution by Location of Headquarters (in Million Liters)
Table 13.47 Global Plasma Fractionation Market (Historical, Base and Forecasted Scenario), 2017-2035 (USD Billion)
Table 13.48 Plasma Fractionation Market: Distribution by Type of Company, 2017, 2023 and 2035 (USD Billion)
Table 13.49 Plasma Fractionation Market for In-house Manufacturers, 2023-2035 (USD Billion)
Table 13.50 Plasma Fractionation Market for Contract Service Providers, 2023-2035 (USD Billion)
Table 13.51 Plasma Fractionation Market: Distribution by Scale of Operation, 2017, 2023 and 2035 (USD Billion)
Table 13.52 Plasma Fractionation Market for Preclinical Operations, 2023-2035 (USD Billion)
Table 13.53 Plasma Fractionation Market for Clinical Operations, 2023-2035 (USD Billion)
Table 13.54 Plasma Fractionation Market for Commercial Operations, 2023-2035 (USD Billion)
Table 13.55 Plasma Fractionation Market: Distribution by Type of Plasma-derived Therapeutic Products Manufactured, 2017, 2023 and 2035 (USD Billion)
Table 13.56 Plasma Fractionation Market for Albumins, 2023-2035 (USD Billion)
Table 13.57 Plasma Fractionation Market for Coagulation Factors, 2023-2035 (USD Billion)
Table 13.58 Plasma Fractionation Market for Immunoglobulins, 2023-2035 (USD Billion)
Table 13.59 Plasma Fractionation Market for Protease Inhibitors, 2023-2035 (USD Billion)
Table 13.60 Plasma Fractionation Market for Other Plasma-derived Products, 2023-2035 (USD Billion)
Table 13.61 Plasma Fractionation Market: Distribution by Therapeutic Areas of Plasma-derived Products, 2017, 2023 and 2035 (USD Billion)
Table 13.62 Plasma Fractionation Market for Hematological Disorders, 2023-2035 (USD Billion)
Table 13.63 Plasma Fractionation Market for Hepatic Disorders, 2023-2035 (USD Billion)
Table 13.64 Plasma Fractionation Market for Immunological Disorders, 2023-2035 (USD Billion)
Table 13.65 Plasma Fractionation Market for Neurological Disorders, 2023-2035 (USD Billion)
Table 13.66 Plasma Fractionation Market for Other Disorders, 2023-2035 (USD Billion)
Table 13.67 Plasma Fractionation Market: Distribution by Demand across Key Geographical Regions, 2017, 2023 and 2035 (USD Billion)
Table 13.68 Plasma Fractionation Market for North America, 2023-2035 (USD Billion)
Table 13.69 Plasma Fractionation Market for Europe, 2023-2035 (USD Billion)
Table 13.70 Plasma Fractionation Market for Asia-Pacific, 2023-2035 (USD Billion)
Table 13.71 Plasma Fractionation Market for Rest of the World, 2023-2035 (USD Billion)
Table 13.72 Plasma Fractionation Market: Distribution by Supply across Key Geographical Regions, 2017, 2023 and 2035 (USD Billion)
Table 13.73 Plasma Fractionation Market for North America, 2023-2035 (USD Billion)
Table 13.74 Plasma Fractionation Market for Europe, 2023-2035 (USD Billion)
Table 13.75 Plasma Fractionation Market for Asia-Pacific, 2023-2035 (USD Billion)
Table 13.76 Plasma Fractionation Market for Rest of the World, 2023-2035 (USD Billion)
The following companies / institutes / government bodies and organizations have been mentioned in this report:
Source 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001115/
Source 2: https://www.niskanencenter.org/the-case-for-commercial-compensated-plasma-collections/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES